Cargando…

The P2 purinoceptors in prostate cancer

P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer’s grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zilin, Zhu, Sha, Tan, Sirui, Zeng, Yuhao, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984634/
https://www.ncbi.nlm.nih.gov/pubmed/35771310
http://dx.doi.org/10.1007/s11302-022-09874-2
_version_ 1784900777591963648
author Wang, Zilin
Zhu, Sha
Tan, Sirui
Zeng, Yuhao
Zeng, Hao
author_facet Wang, Zilin
Zhu, Sha
Tan, Sirui
Zeng, Yuhao
Zeng, Hao
author_sort Wang, Zilin
collection PubMed
description P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer’s growth and invasiveness. However, the comprehensive mechanisms have yet to be identified. By summarizing the relevant studies, we believe that P2X and P2Y receptors play a dual role in cancer cell growth depending on the prostate cancer microenvironment and different downstream signalling pathways. We also summarized how different signalling pathways contribute to tumor invasiveness and metastasis through P2X and P2Y receptors, focusing on understanding the specific mechanisms led by P2X4, P2X7, and P2Y2. Statins may reduce and prevent tumor progression through P2X7 so that P2X purinergic receptors may have clinical implications in the management of prostate cancer. Furthermore, P2X7 receptors can aid in the early detection of prostate cancer. We hope that this review will provide new insights for future mechanistic and clinical investigations into the role of P2 purinergic receptors in prostate cancer.
format Online
Article
Text
id pubmed-9984634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-99846342023-03-05 The P2 purinoceptors in prostate cancer Wang, Zilin Zhu, Sha Tan, Sirui Zeng, Yuhao Zeng, Hao Purinergic Signal Review Article P2 purinoceptors are composed of ligand-gated ion channel type (P2X receptor) and G protein-coupled metabolite type (P2Y receptor). Both these receptors have played important roles in the prostate cancer microenvironment in recent years. P2X and P2Y receptors can contribute to prostate cancer’s growth and invasiveness. However, the comprehensive mechanisms have yet to be identified. By summarizing the relevant studies, we believe that P2X and P2Y receptors play a dual role in cancer cell growth depending on the prostate cancer microenvironment and different downstream signalling pathways. We also summarized how different signalling pathways contribute to tumor invasiveness and metastasis through P2X and P2Y receptors, focusing on understanding the specific mechanisms led by P2X4, P2X7, and P2Y2. Statins may reduce and prevent tumor progression through P2X7 so that P2X purinergic receptors may have clinical implications in the management of prostate cancer. Furthermore, P2X7 receptors can aid in the early detection of prostate cancer. We hope that this review will provide new insights for future mechanistic and clinical investigations into the role of P2 purinergic receptors in prostate cancer. Springer Netherlands 2022-06-30 2023-03 /pmc/articles/PMC9984634/ /pubmed/35771310 http://dx.doi.org/10.1007/s11302-022-09874-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Wang, Zilin
Zhu, Sha
Tan, Sirui
Zeng, Yuhao
Zeng, Hao
The P2 purinoceptors in prostate cancer
title The P2 purinoceptors in prostate cancer
title_full The P2 purinoceptors in prostate cancer
title_fullStr The P2 purinoceptors in prostate cancer
title_full_unstemmed The P2 purinoceptors in prostate cancer
title_short The P2 purinoceptors in prostate cancer
title_sort p2 purinoceptors in prostate cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984634/
https://www.ncbi.nlm.nih.gov/pubmed/35771310
http://dx.doi.org/10.1007/s11302-022-09874-2
work_keys_str_mv AT wangzilin thep2purinoceptorsinprostatecancer
AT zhusha thep2purinoceptorsinprostatecancer
AT tansirui thep2purinoceptorsinprostatecancer
AT zengyuhao thep2purinoceptorsinprostatecancer
AT zenghao thep2purinoceptorsinprostatecancer
AT wangzilin p2purinoceptorsinprostatecancer
AT zhusha p2purinoceptorsinprostatecancer
AT tansirui p2purinoceptorsinprostatecancer
AT zengyuhao p2purinoceptorsinprostatecancer
AT zenghao p2purinoceptorsinprostatecancer